CN100423753C - 从天然植物复方制剂中提取增强记忆制品药物的方法 - Google Patents
从天然植物复方制剂中提取增强记忆制品药物的方法 Download PDFInfo
- Publication number
- CN100423753C CN100423753C CNB2004100011479A CN200410001147A CN100423753C CN 100423753 C CN100423753 C CN 100423753C CN B2004100011479 A CNB2004100011479 A CN B2004100011479A CN 200410001147 A CN200410001147 A CN 200410001147A CN 100423753 C CN100423753 C CN 100423753C
- Authority
- CN
- China
- Prior art keywords
- radix
- compound product
- medicine
- group
- white mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000005728 strengthening Methods 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000011347 resin Substances 0.000 claims abstract description 17
- 229920005989 resin Polymers 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 13
- 229930014626 natural product Natural products 0.000 claims abstract description 6
- 238000001228 spectrum Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 238000012207 quantitative assay Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 240000002924 Platycladus orientalis Species 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 114
- 241000699670 Mus sp. Species 0.000 description 75
- 230000000694 effects Effects 0.000 description 56
- 102000019197 Superoxide Dismutase Human genes 0.000 description 18
- 108010012715 Superoxide dismutase Proteins 0.000 description 18
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 17
- 206010027175 memory impairment Diseases 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- -1 lipid peroxide Chemical class 0.000 description 15
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 13
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 13
- 229960002646 scopolamine Drugs 0.000 description 13
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 13
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- 229960002275 pentobarbital sodium Drugs 0.000 description 11
- 229960004526 piracetam Drugs 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010039897 Sedation Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000036280 sedation Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010003084 Areflexia Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 3
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 229910000906 Bronze Inorganic materials 0.000 description 2
- 235000016299 Canarium odontophyllum Nutrition 0.000 description 2
- 244000001582 Canarium odontophyllum Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000010974 bronze Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
药物 | 剂量(ml/kg) | 给药时间 | n | 错误反应次数(X±SD) |
NS | 等容 | Bid×7 | 10 | 0.425±0.114 |
复方制品 | 4 | Bid×7 | 10 | 0.293±0.126<sup>**</sup> |
复方制品 | 8 | Bid×7 | 10 | 0.211±0.093<sup>***</sup> |
药物 | 剂量(ml/kg) | 给药时间 | N | 错误反应次数(X±SD) |
NS | 等容 | Bid×7 | 10 | 0.309±0.158 |
NS+东莨菪碱 | 3mg/kg | Bid×7 | 10 | 0.538±0.140TT |
复方制品+东莨菪碱 | 48 | Bid×7Bid×7 | 1010 | 0.370±0.144***0.300±0.110*** |
组别 | 剂量(ml/kg) | 给药时间 | n | SOD活性(X±SD nu/ml) |
NS | 等容 | qd×15 | 10 | 19.8±3.1 |
复方制品 | 4 | qd×15 | 10 | 24.3±4.1<sup>**</sup> |
复方制品 | 8 | qd×15 | 10 | 27.1±2.9<sup>***</sup> |
组别 | 剂量(ml/kg) | n | 小鼠活动次数(X±SD) |
NS | - | 10 | 45.6±26.4 |
复方制品 | 0.2 | 10 | 8.4±5.6<sup>***</sup>T |
复方制品 | 0.1 | 10 | 41.7±18.6<sup>*</sup> |
组别 | 例数 | 临床痊愈 | 显效 | 有效 | 无效 | 显效以上百分率 | 总有效率 |
复方制品 | 100 | 4 | 41 | 44 | 11 | 45% | 29% |
对照组 | 60 | 0 | 9 | 35 | 16 | 15% | 73.3% |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100011479A CN100423753C (zh) | 2004-02-02 | 2004-02-02 | 从天然植物复方制剂中提取增强记忆制品药物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100011479A CN100423753C (zh) | 2004-02-02 | 2004-02-02 | 从天然植物复方制剂中提取增强记忆制品药物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1650895A CN1650895A (zh) | 2005-08-10 |
CN100423753C true CN100423753C (zh) | 2008-10-08 |
Family
ID=34867038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100011479A Expired - Lifetime CN100423753C (zh) | 2004-02-02 | 2004-02-02 | 从天然植物复方制剂中提取增强记忆制品药物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100423753C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102119986B (zh) * | 2011-03-07 | 2013-03-27 | 北京中医药大学 | 一种具有抗痴呆作用的中药提取物及其制备方法 |
CN104688973A (zh) * | 2015-04-02 | 2015-06-10 | 韩桂莲 | 治疗失眠的中药制剂 |
CN105148144A (zh) * | 2015-09-22 | 2015-12-16 | 麻翠秋 | 一种可促进健脑益智的浴足液 |
CN105250642A (zh) * | 2015-10-28 | 2016-01-20 | 雷少华 | 一种治疗失眠的中药组合物 |
CN108949677B (zh) * | 2018-07-05 | 2021-11-30 | 浙江大学 | 地黄苷c和丹酚酸a在促进体外培养骨髓间充质干细胞增殖和抑制复制性衰老中的应用 |
CN111366672B (zh) * | 2020-04-24 | 2021-06-22 | 劲牌有限公司 | 一种保健酒指纹图谱的检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1153046A (zh) * | 1995-12-26 | 1997-07-02 | 沈阳科进工程有限公司 | 护脑液 |
-
2004
- 2004-02-02 CN CNB2004100011479A patent/CN100423753C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1153046A (zh) * | 1995-12-26 | 1997-07-02 | 沈阳科进工程有限公司 | 护脑液 |
Also Published As
Publication number | Publication date |
---|---|
CN1650895A (zh) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100435831C (zh) | 治疗高血压、高血脂、肥胖症及更年期综合症的制剂及其制备方法 | |
CN101708281B (zh) | 一种养心安神的中药制剂及其制备方法 | |
CN107126485A (zh) | 一种辅助改善睡眠的中药组合物及其制备方法和应用 | |
CN100493597C (zh) | 一种用于治疗神经症的药物组合物 | |
CN105663607A (zh) | 一种中药组合物及其制备方法和用途 | |
CN101711847B (zh) | 一种治疗抑郁症、焦虑症的口服中药制剂 | |
CN100423753C (zh) | 从天然植物复方制剂中提取增强记忆制品药物的方法 | |
CN101584796B (zh) | 一种中药组合物在制备治疗抑郁症的药物中的应用 | |
CN106421579B (zh) | 一种治疗疲劳的中药组合物及其制备方法 | |
CN103181949A (zh) | 一种镇静安神口服制剂及其制备方法 | |
CN101919962B (zh) | 一种治疗失眠的药物及其制备方法 | |
CN101912597A (zh) | 一种治疗老年性痴呆症的药物及其制备方法 | |
CN1325099C (zh) | 治疗失眠症的中药胶囊 | |
CN102488830A (zh) | 一种降血糖的药物组合物 | |
CN105582274A (zh) | 一种治疗女性更年期综合征的药物组合物及其制备方法 | |
CN102784230B (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN115252753A (zh) | 治疗失眠的中药组合物及其应用 | |
CN106237268A (zh) | 一种治疗精神***症的药物组合物及其应用 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN106581299B (zh) | 一种改善中老年肾气虚证的中药组合物及其应用 | |
CN112076276B (zh) | 一种治疗过敏性鼻炎的药物组合物及其制备方法 | |
CN102716448A (zh) | 能够有效治疗恶心呕吐的中成药及中药汤剂 | |
CN100571722C (zh) | 治疗肾虚及更年期综合症的药物组合物及其制备方法 | |
CN102416147B (zh) | 一种治疗戒毒人员的躁狂症的药物组合物 | |
CN105288186A (zh) | 用于医治抑郁症的疏肝理气制剂及制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Fan Nanxing Document name: Notification of registration procedures and notice of patent for invention |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENYANG FEILONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANG WEI Effective date: 20140207 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110166 SHENYANG, LIAONING PROVINCE TO: 110300 SHENYANG, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140207 Address after: 110300 Xinmin Industrial Zone, Liaoning Patentee after: Shenyang Feilong Pharmaceutical Co.,Ltd. Address before: Hunnan New District Road Shenyang city Liaoning province 110166 No. 9 A203 Patentee before: Jiang Wei |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20081008 |
|
CX01 | Expiry of patent term |